- Company
- Expectations on Zejula are high
- by Sep 14, 2020 06:15am
- “The biggest burden on recurrent ovarian cancer patients is definitely 'relapse'. Zejula can play an important role for patients by preventing recurrence through primary maintenance therapy. In particular, it can be used as an All-comer. The appearance of Zejula is likely to make a big difference in the treatment of ovarian cancer.” Soo
- Company
- Kolmar shareholders agree to dispose CMO and Kolmar Pharma
- by Chon, Seung-Hyun Sep 14, 2020 06:15am
- Kolmar Korea’s shareholders have agreed to dispose of the corporate asset valued at 500 billion won. Kolmar Korea announced the shareholders have deliberated at a general meeting convened on Sept. 10 to pass the agenda of selling the company’s pharmaceutical CMO and Kolmar Pharma to IMM Private Equity (PE). Previously in last May, Kolm
- Company
- The issue is that the NHIS is entitled to indemnity or not
- by Kim, Jin-Gu Sep 14, 2020 06:14am
- A legal dispute has begun between the NHIS and 36 domestic pharmaceutical companies regarding Valsartan's claim for right to indemnity. At the first trial, the issue emerged as an issue whether the NHIS exercises the right to indemnit. The judiciary questioned whether they were eligible to claim from the NHIS, not from patients under the
- Company
- Korean drug industry prepares for Peramiflu generic
- by Kim, Jin-Gu Sep 11, 2020 06:29am
- South Korean pharmaceutical companies are speeding up the launch preparation for a flu drug Peramiflu (peramivir) generic. After filing trials for invalidation of original patent late last year, ten pharmaceutical companies recently applied for the generic approval. If Ministry of Food and Drug Safety (MFDS) approves the generic and the
- Company
- Qurient, expects a big deal for Q203, Q301, Q702, & Q901
- by An, Kyung-Jin Sep 11, 2020 06:28am
- There are high expectations for Qurient to sign a large technology transfer contract in the second half of the year. All four key tasks, including immune anticancer drugs, atopic dermatitis and multi-drug-resistant tuberculosis treatment, are all in the process of discussing technology export, and there is a possibility that at least one contrac
- Policy
- GSK withdraws adult TD vaccine from Korea
- by Lee, Tak-Sun Sep 11, 2020 06:28am
- GSK will stop supplying the adult TD vaccine 'Td-pur', which was imported and sold in Korea. The company said there was no additional import after November 30. Until now, adult TD vaccines have been dependent on imports, but GC Pharma succeeded in localizing them in 2016. With GSK's supply discontinuation of Td-pur, the localization of GC
- Policy
- First drug for ultra rare Batten disease Brineura approved
- by Lee, Tak-Sun Sep 11, 2020 06:28am
- The first treatment for a pediatric rare disease, Batten disease, has received the South Korean health authority’s approval. As Batten disease is an inherited metabolic disorder that can cause loss of sight, the new treatment could give hopes to the patients and their families. Ministry of Food and Drug Safety (MFDS) has approved Brineura 1
- Company
- Hunterase by GC Pharma is entering the Chinese market
- by Chon, Seung-Hyun Sep 11, 2020 06:28am
- Hunterase by Green Cross is entering the Chinese market GC Pharma announced on the 9th that Hunterase, a treatment for Hunter syndrome, has obtained a license from the NMPA of China. This is the first time that a drug for Hunter syndrome has been approved in China. GC Pharma applied for Hunterase's item license, July of last year in Chi
- Company
- Hanmi to turn efpeglenatide crisis around with new partner
- by An, Kyung-Jin Sep 10, 2020 06:24am
- Hanmi Pharmaceutical’s glucagon-like peptide-1 (GLP-1) agonist ‘efpeglenatide,’ initially licensed out to a global pharmaceutical company Sanofi in 2015, was ultimately returned to the South Korean company. Four months after when the global company indicated its intention to return the rights on the drug May, Sanofi has decided to suspend
- Product
- 10,000 pros & cons for generic substitution
- by Kim, Min-Gun Sep 10, 2020 06:23am
- There are a lot of unusual comments in the National Assembly legislation, where not even a single comment is usually posted. These are the 'Simplification Act for Generic Substitution Post Notification' and 'The Act on Restriction of 1+3 Joint Biological Equivalence'. All of them are laws related to the issue of generc prescription. Among the
